Skip to main content
Premium Trial:

Request an Annual Quote

Vysis Expands Genetic Workstations Sales


DOWNERS GROVE, Ill.--Vysis, a genomic disease management company here specializing in clinical products for evaluating and managing cancer, prenatal disorders, and other genetic diseases, signed agreements in February that will broaden its worldwide coverage to include Mexico, Brazil, and Southern Africa and expand its distributor relationship in Spain. Vysis CEO John Bishop said the company will continue to add distributors to make its clinical and research products and genetic workstations available to clinical labs around the world.

In Mexico and Brazil, Omnichem of Mexico City will distribute Vysis products. In Southern Africa, BDS Diagnostics of Pretoria, South Africa, will handle distribution. Spanish distributor Isaza of Barcelona will market one of Vysis's first clinically approved prenatal products for the early detection of genetic abnormalities associated with mental retardation and other birth defects. Vysis genetic workstations utilize proprietary Fluorescence In Situ Hybridization (FISH) test platforms.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.